Serendipity And Science: Forging Billion-Dollar Oncology Breakthroughs

Through serendipity, science, and rigor, SpringWorks Therapeutics, a targeted oncology company, marks success with the first FDA-approved treatment for Desmoid Tumor.

Related Keywords

United States ,American ,Ogsiveo Nirogacestat ,Shivaani Kummar ,Dana Lawson ,Badreddin Edris ,Saqib Islam ,Marlene Portnoy ,Jeanne Whiting ,Alexion Pharmaceuticals ,American Association For Cancer Research ,Bain Capital Life Sciences ,Pfizer ,Desmoid Tumor Research Foundation ,European Organization For Research ,National Cancer Institute ,Works Therapeutics ,Desmoid Tumors ,Desmoid Tumor ,European Organization ,American Association ,Cancer Research ,Springworks Therapeutic ,Springworks Therapeutics ,Neurofibromatosis Type ,Associated Plexiform Neurofibromas ,Chief Business Officer ,Chief Financial Officer ,New England Journal ,Multiple Myeloma ,Moderna Therapeutics ,Executive Vice President ,Chief Strategy ,Portfolio Officer ,Managing Director ,Morgan Stanley ,Springworks Therapeutic Chief Operating Officer ,Oncology ,Rare Disease ,Life Science Innovation ,Healthcare Innovation ,Biotechnology ,